# CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

> **NCT02912455** · PHASE4 · TERMINATED · sponsor: **The Cleveland Clinic** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Obesity

## Interventions

- **DRUG:** canagliflozin
- **DRUG:** Placebo (for canagliflozin)

## Key facts

- **NCT ID:** NCT02912455
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-05
- **Primary completion:** 2018-07-19
- **Final completion:** 2018-07-19
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study was terminated due to difficulty with reaching enrollment goals
- **Last updated:** 2020-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02912455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02912455, "CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02912455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*